ライフサイエンスコーパス: bispecific antibody

1 ed in the same cell to assemble a functional bispecific antibody.

2 fficiently in the presence of the CD70-fiber bispecific antibody.

3 e-related variants in an IgG1 knob-into-hole bispecific antibody.

4 tent antibodies and explore the potential of bispecific antibodies.

5 Using this approach, we produce 28 unique bispecific antibodies.

6 d in the same cell to generate heterodimeric bispecific antibodies.

7 ction provides a novel synthetic approach to bispecific antibodies.

8 small-scale generation of human full-length bispecific antibodies.

9 armacophores to generate optimized or unique bispecific antibodies.

10 ltaneous targeting of two tumor targets with bispecific antibodies.

11 and improved sources of clinically relevant bispecific antibodies.

12 as with chimeric antigen receptor T cells or bispecific antibodies.

13 ery with possible functional implications in bispecific antibodies.

14 One bispecific antibody, 10E8V2.0/iMab, neutralized 118 HIV-

15 We produced a bispecific antibody (3F12) which binds influenza virus M

16 With the recent clinical success of bispecific antibodies, a strategy to rapidly synthesize

17 nd, we produced a recombinant human IgG-like bispecific antibody, a Di-diabody, using the variable re

18 NA to reduce antithrombin expression and the bispecific antibody ACE910/emicizumab.

19 The CD30/CD16A-bispecific antibody AFM13 is an innate immune cell engag

20 Synergistic bispecific antibodies against HIV exhibit extraordinary

21 We have shown that bispecific antibodies against TfR and beta-secretase (BA

22 We report a bispecific antibody against B cell maturation antigen (B

23 A bispecific antibody against the receptor tyrosine kinase

24 Here, we describe the synthesis of a novel bispecific antibody, alphaCLL1-alphaCD3, using the genet

25 mune activation of cytotoxic effector cells, bispecific antibodies and antibodies linked to superanti

26 Bispecific antibodies and antibody fragments are a new c

27 rogeneous biopharmaceutical products such as bispecific antibodies and antibody mixtures.

28 ntibody-drug conjugates, conjugate vaccines, bispecific antibodies and cell therapy.

29 disulfide bonds in both half antibodies and bispecific antibodies and identifying cysteine-related m

30 These results support this new approach to bispecific antibodies and offer a potential new strategy

31 successfully redirected to tumor cells using bispecific antibodies and offer a promising strategy for

32 throughput analyses of antibodies, including bispecific antibodies and potential mispaired side produ

33 Bispecific antibodies and recombinant proteins are also

34 rved following administration of natural and bispecific antibodies and, more recently, following adop

35 ased on a glycoprotein A33 (GPA33)-targeting bispecific antibody and a small-molecule radioactive hap

36 Bispecific antibody and antibody-like molecules are of w

37 pecific therapeutics, including immunotoxin, bispecific antibody and chimeric antigen receptor T cell

38 Psl, and susceptibility to the anti-PcrV/Psl bispecific antibody and clinical candidate MEDI3902.

39 undergo in vivo Fab arm exchange leading to bispecific antibody and off-target effects.

40 Fc containing therapeutics (e.g. antibodies, bispecific antibodies, and Fc fusions) requiring lack of

41 , leading to the formation of monovalent but bispecific antibodies, and it interacts poorly with Fcga

42 position of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate

43 overed such as monoclonal antibodies (mAbs), bispecific antibodies, antibody drug conjugates (ADCs),

44 ess in research on intracellular antibodies, bispecific antibodies, antibody-fusion molecules, and an

45 otein-coupled receptors using a BBB-crossing bispecific antibody approach and emerging principles tha

46 Bispecific antibodies are asymmetrical compared to their

47 Bispecific antibodies are considered attractive bio-ther

48 the generation of large numbers of different bispecific antibodies are presented.

49 These results suggest that IgG-based bispecific antibodies are promising candidates for the p

50 Bispecific antibodies are regarded as the next generatio

51 However, FVIII and the bispecific antibody are fundamentally different proteins

52 Chimeric proteins, including bispecific antibodies, are biological tools with therape

53 ignaling pathways were evaluated during EGFR bispecific antibody armed ATC (aATC)-mediated killing of

54 The development of bispecific antibodies as therapeutic agents for human di

55 payloads such as other antibodies to create bispecific antibodies as well as organic and non-organic

56 be the creation and production of plant-made bispecific antibodies based on trastuzumab and pertuzuma

57 Bispecific antibody-based therapeutics for the treatment

58 nity Re-Targeting (DART) proteins, which are bispecific, antibody-based molecules that can bind 2 dis

59 Comparison with a single-chain, bispecific antibody bearing identical CD19 and CD3 antib

60 Chemically programmed bispecific antibodies (biAbs) endow target cell-binding

61 Bispecific antibodies (biAbs) that mediate cytotoxicity

62 o 20-fold more potently than a CS1-targeting bispecific antibody (BiFab-CS1) developed in an analogou

63 this approach to the development of chimeric bispecific antibody binding site (chi BABS) proteins.

64 e used antibody engineering to develop novel bispecific antibodies (Bis-mAbs) that are cross-reactive

65 e observed for the expression of therapeutic bispecific antibodies (BisAbs) is high product aggregate

66 pecificities can dissociate and recombine in bispecific antibodies both in vitro and in vivo.

67 ltaneous engagement of two distinct targets, bispecific antibodies broaden the potential utility of a

68 We previously described a highly flexible bispecific antibody (bs-mAb) pretargeting procedure usin

69 ied using PrA-MS and are presented here: (a) bispecific antibodies (bsAb) and (b) glycan engineered a

70 Methods to rapidly generate high quality bispecific antibodies (BsAb) having normal half-lives ar

71 nical studies to date have demonstrated that bispecific antibodies (BsAb) may have potentially signif

72 The use of bispecific antibodies (BsAb) provides integration of the

73 T cell-recruiting bispecific antibodies (bsAb) show promise in hematologic

74 Bispecific antibodies (bsAb) that bridge tumor cells and

75 ted and produced two fully human recombinant bispecific antibodies (BsAb) that target both EGFR and I

76 ectively targeted against malignant B cells, bispecific antibodies (BsAb) were constructed from two a

77 s such as antibody-drug conjugates (ADC) and bispecific antibodies (bsAb), are the fastest growing cl

78 d DNL to generate a novel class of trivalent bispecific antibodies (bsAb), each comprising an anti-CD

79 for the generation of therapeutic human IgG1 bispecific antibodies (bsAb).

80 ived macrophages mediated by MAb DF3 and its bispecific antibody (BsAb) DF3xH22 with the second epito

81 ation of homodimer impurities in therapeutic bispecific antibody (bsAb) drug products is essential to

82 The term bispecific antibody (bsAb) is used to describe a large f

83 A bispecific antibody (BsAb) targeting the epidermal growt

84 In order to target alpha v integrins, a bispecific antibody (bsAb) that comprised a monoclonal A

85 inical evaluation of a recombinant AC133xCD3 bispecific antibody (bsAb) that redirects human polyclon

86 Among these, a Her2 x CD3 bispecific antibody (BsAb) was constructed by inserting

87 These deficiencies were overcome by using a bispecific antibody (bsAb) with specificities for human

88 Bispecific antibodies (bsAbs) and antibody-drug conjugat

89 Bispecific antibodies (bsAbs) are Abs composed of two di

90 Bispecific antibodies (bsAbs) are of significant importa

91 Bispecific antibodies (bsAbs) are one of the most versat

92 Bispecific antibodies (BsAbs) are regarded as promising

93 Bispecific antibodies (bsAbs) combine the antigen specif

94 a pair of humanized hexavalent anti-CD20/22 bispecific antibodies (bsAbs) derived from veltuzumab (v

95 We prepared bispecific antibodies (bsAbs) for disease-specific targe

96 Many methods have been developed to produce bispecific antibodies (BsAbs) for industrial application

97 Bispecific antibodies (BsAbs) have drawn increasing inte

98 Generation of bispecific antibodies (BsAbs) having two unique Fab doma

99 cacy of engaging multiple drug targets using bispecific antibodies (BsAbs) is affected by the relativ

100 g T cells to hematological malignancies with bispecific antibodies (BsAbs) is an attractive strategy.

101 Producing pure and well behaved bispecific antibodies (bsAbs) on a large scale for precl

102 Bispecific antibodies (BsAbs) target multiple epitopes o

103 Bispecific antibodies (bsAbs) that lack the immunoglobul

104 The promise of bispecific antibodies (bsAbs) to yield more effective th

105 Four different formats of bispecific antibodies (bsAbs) were generated that consis

106 onal mouse anti-TnI IgG mAb 265, (2) TnI and bispecific antibodies (BsAbs) which on one end recognize

107 This results in functionally monovalent, bispecific antibodies (bsAbs) with unknown specificity a

108 Bispecific antibodies (BsAbs), with a unique mechanism o

109 Bispecific antibodies (bscAbs), particularly those of th

110 chimeric anticarcinoembryonic antigen (CEA) bispecific antibody (BsMAb) and peptides labeled with (1

111 ing method using a new recombinant anti-CD20 bispecific antibody (bsMAb) followed by (90)Y-1,4,7,10-t

112 A flexible bispecific antibody (bsMAb) multistep, pretargeting syst

113 Bispecific antibodies, but not parent mAbs, neutralized

114 hole approach is an effective way to produce bispecific antibodies by driving heterodimerization with

115 icient heavy-chain assembly of heterodimeric bispecific antibodies by exchanging the interdomain prot

116 We have produced novel bispecific antibodies by fusing the DNA encoding a singl

117 rm of generating bispecific IgG antibodies, "Bispecific Antibody by Protein Trans-splicing (BAPTS)".

118 e, we review the principle of a new class of bispecific antibodies called BiTE (for "bispecific T-cel

119 We show that IgG4 bispecific antibodies can be generated in large quantiti

120 Bispecific antibodies can be used to redirect cytotoxic

121 us, Ad) vectors targeted to CD40 by means of bispecific antibodies can enhance gene transfer to murin

122 These results indicate that the CD70-fiber bispecific antibody can enhance rAd infection of CD70-po

123 he two parental antibodies and that a single bispecific antibody can neutralize 97% of viral strains

124 Bispecific antibodies capable of redirecting the lytic p

125 Bispecific antibodies combine two different antigen-bind

126 egies predicated on streptavidin and biotin, bispecific antibodies, complementary oligonucleotides, a

127 act specifically with the capture arm of the bispecific antibody complex were used to demonstrate the

128 Use of bispecific antibody complexes and (99m)Tc-DTPA-succinyl-

129 Bispecific antibody complexes and (99m)Tc-labeled negati

130 vel, potently neutralizing, tetravalent, and bispecific antibody composed of 2 heavy-chain-only VH (V

131 nsfer specifically to tumor cells, we used a bispecific antibody conjugate to ablate Ad binding to fi

132 en with the addition of novel monoclonal and bispecific antibody constructs targeting CD19 and CD22 m

133 Here we show that bispecific antibodies contain the binding specificities

134 n leukemic cytotoxic T cells triggered via a bispecific antibody containing an anti-CD3 F(ab') to kil

135 l trials have been initiated to test whether bispecific antibodies could redirect immune effectors ag

136 dentical for native diphtheria toxin and the bispecific antibody. CRM107 combination.

137 However, bispecific-antibody design and production remain challen

138 d a DropArray cell-based assay to evaluate a bispecific antibody designed to engage cytotoxic T cells

139 or TNBC and emerging TNBC targets for future bispecific antibody development.

140 sozyme-specific antibody fragments, creating bispecific antibodies (diabodies).

141 Bispecific antibodies directed against transferrin recep

142 Catumaxomab (CatmAb), a trifunctional bispecific antibody directed against the epithelial cell

143 nded the technology by developing a two-part bispecific antibody discovery strategy that facilitates

144 In contrast, the bispecific antibody does not enhance Ad-GFP infection in

145 This bispecific antibody efficiently induces targeted cell ly

146 The bispecific antibody emicizumab is increasingly used for

147 All 3 bispecific antibodies exhibited identical pharmacokineti

148 er T (NKT) cells retargeted with a humanized bispecific antibody F(ab')(2)HER2xCD3.

149 tional monoclonal antibodies, knob-into-hole bispecific antibodies face unique challenges in producti

150 experiments revealed that high-affinity TfR bispecific antibodies facilitated the trafficking of TfR

151 To counter this problem, we developed a bispecific antibody (FIT-1) comprising ZKA190 and a seco

152 usion: Immuno-PET using anti-CEA/anti-IMP288 bispecific antibody, followed by (68)Ga-IMP288, is a pot

153 ath to generating highly effector-attenuated bispecific antibodies for preclinical studies.

154 These findings support the use of bispecific antibodies for the prevention or treatment of

155 ong implications for the design of efficient bispecific antibodies for therapeutic applications.

156 The present review discusses novel bispecific antibodies for TNBC and emerging TNBC targets

157 h the identification of a common light chain bispecific antibody for large-scale production with high

158 adionuclides, a new anti-Trop-2 x antihapten bispecific antibody for pretargeting, based on humanized

159 While the clinical potential for certain bispecific antibody formats is clear, progress has been

160 en hindered by the difficulty of identifying bispecific antibody formats that exhibit favorable pharm

161 We describe the use of a bispecific antibody fragment (diabody) to recruit the wh

162 The therapeutic potential of bispecific antibody fragments and Fc-containing proteins

163 the construction of other disease-targeting bispecific antibody fragments for early detection and di

164 provides a versatile platform for generating bispecific antibody fragments for redirected killing and

165 Our strategy allows rapid generation of bispecific antibodies from any two existing antibodies a

166 increasing number of multivalent antibodies, bispecific antibodies, fusion proteins, and targeted nan

167 Robust generation of IgG bispecific antibodies has been a long-standing challenge

168 d, following conversion to a T cell-engaging bispecific antibody, has potent cytotoxicity toward ROR2

169 Although human IgG1 bispecific antibodies have been generated, few attempts

170 Bispecific antibodies have been used in different cell s

171 Human bispecific antibodies have great potential for the treat

172 Bispecific antibodies have great potential to be the nex

173 orm conventional monoclonal antibodies, many bispecific antibodies have issues regarding production,

174 Many different formats of bispecific antibodies have meanwhile been developed.

175 Such "Trojan horse" bispecific antibodies have potential as broad antifilovi

176 nerality of the approach and show that these bispecific antibodies have properties similar to those o

177 Bispecific antibodies have received wide attention as pr

178 Bispecific antibodies have therapeutic potential by expa

179 eting" methods, particularly those utilizing bispecific antibodies, have greatly enhanced the therape

180 Bispecific antibodies having binding specificities for t

181 this study, we describe a trastuzumab-based bispecific antibody, HER2-TDB, which targets HER2 and co

182 ti-diethylenetriaminepentaacetic acid (DTPA) bispecific antibody (hMN-14 x m734) (40 mg/m(2)), follow

183 These bispecific antibodies hold promise as novel prophylactic

184 l binding scaffolds, activatable antibodies, bispecific antibodies, immunocytokines, antibody-drug co

185 i-CD30 antibodies as well as anti-CD30-based bispecific antibodies, immunotoxins, and radioimmunoconj

186 scaffolds offers the possibility to produce bispecific antibodies in vitro.

187 Comparing high- and low-affinity TfR bispecific antibodies in vivo, we found that high-affini

188 In this study, we characterized bispecific antibodies in which a BBB-crossing antibody f

189 The engineering of bispecific antibodies in which a therapeutic "arm" is co

190 g, this mechanism leads to the production of bispecific antibodies in which the LAIR1 domain is preci

191 Bispecific antibodies, including bispecific IgG, show so

192 We demonstrate here that a bispecific antibody incorporating a broadly reactive ant

193 c potential of T cells engaged by a BCMAxCD3-bispecific antibody increased notably with the depletion

194 in advance of the radiolabeled veltuzumab or bispecific antibody injection, tumor uptake was signific

195 T-cell-directed killing of tumor cells using bispecific antibodies is a promising approach for the tr

196 However, analysis of bispecific antibodies is challenging because multiple fo

197 This unique antiangiogenic bispecific antibody is in phase-1 clinical trials.

198 Bispecific antibody is synthesized by covalently linking

199 s of the efficient small-scale generation of bispecific antibodies lacking a common light chain and t

200 , semisynthetic method for the production of bispecific antibody-like therapeutics in which a derivat

201 usion proteins, antibody-drug conjugates, or bispecific antibodies may undergo biotransformation (suc

202 Using the DEKK format, we generated the bispecific antibody MCLA-128, targeting human EGF recept

203 A bispecific antibody, MDX-H210, was developed to target c

204 totoxic potential, however, was restored via bispecific antibody-mediated delivery and release within

205 Comparisons between two versions of the bispecific antibody molecule and analysis of stressed sa

206 Using bispecific antibodies of different valencies to cell sur

207 Emerging bispecific antibodies offer the potential for even bette

208 corporation of FC5 as the BBB-carrier arm in bispecific antibodies or antibody-drug conjugates offers

209 sent an opportunity for approaches utilizing bispecific antibodies or chimeric antigen receptor T cel

210 ernative using either (strept)avidin/biotin, bispecific antibodies, or oligomers.

211 We describe the application of a novel, bispecific antibody platform termed dual affinity retarg

212 We developed a modular bispecific antibody platform that directs the complement

213 A BCMA-targeted bispecific antibody presents a promising treatment optio

214 e dramatically improved therapeutic index of bispecific antibody pretargeting appears to be sufficien

215 Bispecific antibody pretargeting has a significant advan

216 Bispecific antibody pretargeting is highly sensitive and

217 Bispecific antibody pretargeting is highly specific for

218 s applied to a peptide suitable for use in a bispecific antibody pretargeting method.

219 ability, enabling efficient knobs-into-holes bispecific antibody production and a robust path to gene

220 lection of clones with the highest purity of bispecific antibody production and the results significa

221 Here we present a bispecific-antibody production strategy that relies on c

222 R suggest avenues for the development of new bispecific antibody-promoted treatment strategies.

223 Emicizumab is a bispecific antibody recognizing both the enzyme factor I

224 Most analyses of bispecific antibodies rely on liquid chromatography with

225 Bispecific antibodies represent one such strategy in whi

226 o half antibodies to form the knob-into-hole bispecific antibody requires an additional in vitro asse

227 This innovative bispecific antibody scaffold that simultaneously engages

228 an affinity-enhancement system consisting of bispecific antibodies separating targeting from delivery

229 Bispecific antibodies show great promise as intrinsic co

230 ing distinct facets of fracture healing, the bispecific antibody shows superior bone repair activity

231 ites, we have focused on the construction of bispecific antibodies specific for the tumor antigen HER

232 Here, we describe a bispecific-antibody strategy to target this interaction,

233 s and yields milligram to gram quantities of bispecific antibodies sufficient for a wide range of dis

234 e have applied this technology to generate a bispecific antibody suitable for development as a human

235 ed safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2 and vascula

236 ErbB3 ligands is blocked by the tetravalent bispecific antibody targeting IGF-1R and ErbB3, istiratu

237 We also demonstrate that a bispecific antibody, targeting a c-Myc tag on CAR T cell

238 T-cell bispecific antibodies (TCBs) crosslink tumor and T-cells

239 "Off-the-shelf" T-cell bispecific antibodies (TCBs) targeting B-cell maturation

240 The anti-FcRH5/CD3 T cell-dependent bispecific antibody (TDB) targets the B cell lineage mar

241 T-cell-dependent bispecific antibodies (TDBs) are promising cancer immuno

242 port our work expanding the knobs-into-holes bispecific antibody technology to the human IgG4 isotype

243 state cancer using an anti-TROP-2 x anti-HSG bispecific antibody (TF12) in conjunction with the dual-

244 The anti-Trop-2 x antihapten bispecific antibody, TF12, was prepared using the modula

245 onic tumors pretargeted with an anti-CEACAM5 bispecific antibody (TF2).

246 Here, we report engineered bispecific antibodies that are the most potent and broad

247 gammadelta T-cell cytotoxicity, we designed bispecific antibodies that bind CD3 or Vgamma9 on gammad

248 g sites, such as epratuzumab and HU1D10, and bispecific antibodies that can directly interact with ce

249 latform for the mammalian cell production of bispecific antibodies that differ from their parental mA

250 odies that utilize a common light chain, and bispecific antibodies that pair light chains to their co

251 With this approach, we generated potent bispecific antibodies that recruit cytotoxic T lymphocyt

252 Recently, bispecific antibodies that redirect the cytotoxic activi

253 Taken together, our results show how bispecific antibodies that selectively recruit gammadelt

254 antibody constructs including one-armed Abs, bispecific antibodies that utilize a common light chain,

255 Emicizumab, a bispecific antibody that acts as a substitutive therapy

256 pretargeting" approach through engineering a bispecific antibody that binds both cell-surface ICAM-1

257 As a prototype, we developed a bispecific antibody that binds both vascular endothelial

258 eloid-Specific TNF Inhibitor)--a recombinant bispecific antibody that binds to the F4/80 surface mole

259 the technology with an example of a CD3/CD20 bispecific antibody that effectively depletes B cells in

260 A bispecific antibody that has two different antibody bind

261 by this prediction, we engineered MM-131, a bispecific antibody that is monovalent for both Met and

262 rmined whether therapeutic responses using a bispecific antibody that pretargeted (90)Y-hapten-peptid

263 ells and describe JNJ-64407564, a GPRC5DxCD3 bispecific antibody that recruits CD3+ T cells to GPRC5D

264 We apply this approach to generate a bispecific antibody that targets IL-4 and IL-13, two cyt

265 otein interface design to create therapeutic bispecific antibodies, the engineering of light-inducibl

266 For bispecific antibodies, the ratio of the expression level

267 oint inhibitors, adoptive cell transfer, and bispecific antibody therapy.

268 tibodies enables the clinical application of bispecific antibodies to a validated therapeutic pathway

269 ted in the scientific literature that extend bispecific antibodies to other human antibody isotypes.

270 The ability of bispecific antibodies to simultaneously bind two unique

271 racer in situ by pretargeting a multivalent, bispecific antibody to carcinoembryonic antigen (CEA), w

272 Here, we engineered a bispecific antibody to detect K11/K48-linked chains and

273 domain of human tissue factor, by means of a bispecific antibody, to an experimentally induced marker

274 Abs with the potency of cytotoxic agents via bispecific antibody-toxin conjugation.

275 e, we describe a new approach for generating bispecific antibodies using a common light chain format

276 variant generated during the production of a bispecific antibody using the knob-into-hole heterodimer

277 The dual binding capacity of the bispecific antibodies was confirmed by delivery of 125I-

278 As proof-of-concept, a bispecific antibody was employed as an adaptor that phys

279 ons triggered by XGFR, the Fc portion of the bispecific antibody was glycoengineered, which resulted

280 Using the CD70-fiber bispecific antibody, we increased the ability of rAd vec

281 Bispecific antibodies were constructed using genetically

282 Bispecific antibodies were designed to deliver a reversi

283 Approximately 40 microg of bispecific antibodies were injected intravenously after

284 sing T-cell engaging immunotherapies such as bispecific antibodies which target T cells and tumor cel

285 apid generation and chemical optimization of bispecific antibodies, which are termed bispecific CovX-

286 Bispecific antibodies, which simultaneously target CD3 o

287 ology to develop a heterodimeric OAscFab-IgG bispecific antibody, which combines potent signaling inh

288 proach, we synthesized an anti-HER2/anti-CD3 bispecific antibody, which efficiently cross-linked HER2

289 des additional options for the generation of bispecific antibodies with differing effector functions

290 t of patients with malignant gliomas, and of bispecific antibodies with hapten-radionuclides in the t

291 broadens the range of published therapeutic bispecific antibodies with natural surface architecture

292 e efficient heterodimerization, resulting in bispecific antibodies with physiochemical properties ver

293 Labeling of bispecific antibodies with single-photon-emitting isotop

294 The digestion of a bispecific antibody with competitive inhibition of asper

295 itions, resulting in a formation of a stable bispecific antibody with high yields.

296 ases bone mass, we engineer a first-in-class bispecific antibody with single residue pair mutations i

297 We therefore investigated whether a bispecific antibody with specificities for the adenoviru

298 ultaneous targeting of both receptors with a bispecific antibody would lead to enhanced antitumor act

299 The bispecific antibody XGFR is based on the "knob-into-hole

300 owever, most approaches utilized to generate bispecific antibodies yield antibody-like structures tha